Wiley’s Finest Introduces High Potency EPA/DHA With Vitamin K2

14 Mar 2017 --- Nattopharma has announced that its visionary partner, Ohio-based Wiley’s Finest Wild Alaskan Fish Oil, is preparing to launch its Adult EPA and DHA Omega-3 formula featuring MenaQ7 Vitamin K2 as MK-7. The Adult formula is the second product from Wiley’s Finest featuring MenaQ7.                                                                      

The new product combines both 500mg of concentrated EPA and DHA Omega-3 from Alaska Pollock Fish Oil with a meaningful dosage of MenaQ7 K2 per serving (80mcg). Wiley’s opted for this dose after reviewing studies that showed MenaQ7 K2 delivered positive health benefits at just 45mcg per day.

“Playing off the fact that Vitamin K2 is both a key nutrient in this formula and the name of the second highest mountain on earth, we decided to launch this product with the campaign theme of ‘Climb the Peak of Health’. We felt it would be a fun and inspirational way to engage our valued customers and encourage them to rise to the heights of good health,” explains Wiley’s Finest CEO Sam Wiley.

Wiley’s Finest Adult EPA and DHA Omega-3 formula featuring MenaQ7 is the second Wiley’s product including NattoPharma’s clinically validated Vitamin K2 as MK-7. At last year’s Natural Products Expo West Wiley’s launched its award-winning kids liquid formula called Beginner’s DHA. 

Both the child and adult formulas are designed to support bone and cardiovascular health.

The new formula is Contents Tested and Certified by NSF International; this continues Wiley’s Finest’s commitment to exceptional quality as the only full line of Omega-3 Fish Oil supplements that are NSF certified. NSF certification ensures that products meet the dose claimed on their label and are safe from environmental contaminants. Furthermore, each Fish Oil supplement is certified by the Marine Stewardship Council to prove that the wild fish source is sustainably and responsibly caught. 

“Wiley’s insistance on using MenaQ7 Vitamin K2 as MK-7, the clinically validated and patented K2, reiterates their commitment to quality,” says Eric Anderson, senior vice president of global sales and marketing with NattoPharma, the leader in vitamin K2 research and development. “By including MenaQ7 K2 again in their latest product offering, we applaud Wiley's Finest for acknowledging that Vitamin K2 deficiency affects the majority of Western populations. Clinical studies show that Vitamin K2 is an under-consumed nutrient that is very difficult to obtain from diet alone. Wiley’s Finest products offer an important combination with supplemental EPA and DHA Omega-3 to support heart and circulatory health, while delivering bone support simultaneously, for young and now old.”

Kate Quackenbush, Director of Communications tells NutritionInsight: “MenaQ7 is currently available in products across the globe that offer almost every imaginable delivery method (capsules, tablets, melts, emulsions, chewables, liquids, powders, sprays, softgels, gummies, etc.). Our ingredient is available in wide array of dilutions and solubilities, so as part of our MenaQ7 Advance Delivery Platform, we consult with our customers to find the best solution for their desired product application.” 

“Going forward,” Quackenbush adds, “NattoPharma is very excited about the prospect of seeing MenaQ7 become a staple of functional foods. In fact, 2 studies published (Knapen MHJ, et al. J Nutr Sci. 2015; 4:e35.; Knapen MHJ et al. Euro J Clin Nutr (2016), 1-6.) confirm that yogurt and a yogurt drink were effective delivery methods for MenaQ7 Vitamin K2 as MK-7. Really, it's all about bringing our customers' visions to life.”